as a HDAC substrate and shows moderate blood-brain barrier (BBB) permeability and specific signal (by metabolic trapping/or deacetylation) but rapid metabolism. Here, we report the radiosynthesis of two carbon-11 labeled candidate radiotracers (substrate-and inhibitor-based radioligand) for HDAC and their evaluation in non-human primate brain. PET studies showed very low brain uptake and rapid metabolism of both labeled compounds but revealed a surprising enhancement of brain penetration by F for H substitution when comparing one of these to [ 18 F]FAHA. Further structural refinement is needed for the development of brain-penetrant, metabolically stable HDAC radiotracers and to understand the role of fluorine substitution on brain penetration.
a b s t r a c t
Histone deacetylases (HDACs) regulate gene expression by inducing conformational changes in chromatin. Ever since the discovery of a naturally occurring HDAC inhibitor, trichostatin A (TSA) stimulated the recent development of suberoylanilide (SAHA, Zolinza Ò ), HDAC has become an important molecular target for drug development. This has created the need to develop specific in vivo radioligands to study epigenetic regulation and HDAC engagement for drug development for diseases including cancer and psychiatric disorders. 6 as a HDAC substrate and shows moderate blood-brain barrier (BBB) permeability and specific signal (by metabolic trapping/or deacetylation) but rapid metabolism. Here, we report the radiosynthesis of two carbon-11 labeled candidate radiotracers (substrate-and inhibitor-based radioligand) for HDAC and their evaluation in non-human primate brain. PET studies showed very low brain uptake and rapid metabolism of both labeled compounds but revealed a surprising enhancement of brain penetration by F for H substitution when comparing one of these to [
18 F]FAHA. Further structural refinement is needed for the development of brain-penetrant, metabolically stable HDAC radiotracers and to understand the role of fluorine substitution on brain penetration.
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Gene expression is regulated, in part, through enzyme catalyzed epigenetic modifications targeting both the DNA and its associated histone proteins. 1 For example, histone acetyl transferases (HATs) catalyze the acetylation of the lysine residues of histone proteins removing the positive charge and rendering the DNA more accessible to transcription initiation complexes and RNA polymerase. In contrast, histone deacetylases (HDACs) typically catalyze the hydrolysis of the acetyl groups from lysine residues of histone proteins condensing the chromatin and repressing gene expression. 2 Because the folding process induced by the deacetylation of histones represses the expression of genes which are involved in critical metabolic processes such as apoptosis, cell-cycle arrest and differentiation, HDAC has become an important molecular target in drug development. [3] [4] [5] [6] The discovery of a naturally occurring HDAC inhibitor, trichostatin A (TSA, Fig. 1) , 7, 8 an antifungal antibiotic with anticancer activity, has stimulated the development of inhibitors of HDAC including Vorinostat (SAHA, Fig. 1 ) which was recently approved by FDA for the treatment of cutaneous T cell lymphoma (CTCL) and other cancers. 9 HDAC inhibitors are also of interest in the study and treatment of a number of CNS disorders including depression, addiction and neurodegenerative diseases. 4, 10, 11 In fact, valproic acid, a class I HDAC inhibitor, 6 is one of the most widely used and effective antiseizure medications, which we recently showed its poor blood-brain barrier (BBB) penetration explaining the high doses needed for therapeutic efficacy. 12 out to develop a high affinity radiotracer which also crosses the BBB freely and is metabolically stable for PET studies of brain HDAC in humans. Our preference has been to radiolabel with carbon-11 since its short half-life (20.4 min) enables the performance of serial studies in the same day wherein a subject or patients can serve as his/her own control. Herein we report the synthesis of precursors and carbon-11 radiolabeling of two different types of radiotracer candidates, an inhibitor and a substrate (Fig. 3) , and their PET studies in the baboon brain and an analysis of plasma clearance. We predicted that the potent TSA-like HDAC inhibitor 1 (IC 50 , 15 nM for HDAC1) 21 C]acetic acid respectively as labeled metabolites. In addition, we attempted to label M344, which has 4 times higher potency 22 than SAHA, and, although we were not successful, we describe our experience with this difficultto-alkylate aromatic amine. 23 The syntheses of the two hydroxamate reference compounds, 1 and 2, were achieved according to known procedures 21, 22 and their precursors for C-11 labeling were also synthesized as shown Scheme 1. Labeling 1 with [ 11 C]methyl iodide required a 2-step one-pot reaction, first forming the methyl ether followed by conversion to the hydroxamate. This was necessary to avoid preferential [ 11 C]methylation of the hydroxamate moiety under basic conditions. Our initial attempt using a hydroxylamine hydrochloride and strong bases such as sodium hydroxide 24 was not successful due to slow reaction rate and side product formation. However, treatment of the ester with hydroxylamine hydrochloride, using potassium cyanide as a catalyst, 25, 26 converted the ester to the hydroxamate within 5 min. Crude [ 11 C]1 was subsequently purified by high performance liquid chromatography (HPLC). After optimization, the average decay-corrected radiochemical yield (RCY), calculated from 11 CH 3 I, was 23 ± 3% (decay-corrected, n = 3) in a total synthesis time of 50 min. Analytical HPLC and TLC demonstrated that the radiochemical purity was >99% and the specific activity was 280 ± 50 mCi/lmol (n = 3) at the time of administration to the baboon. Radiolabeling of the FAHA analog 3 with C-11 required 2 steps, first formation of [ 11 C]acetyl chloride using from [ 11 C]carboxylation of methylmagnesium bromide followed by treatment with phthaloyl chloride as described previously. 28 Distillation of to determine organ uptake and clearance and regional distribution over 90 min scanning period after intravenous administration. Arterial blood plasma were also collected and counted and selected samples were analyzed using HPLC to measure the fraction of parent labeled compound at different time points during the scan. This information was used to measure the AUC for the parent labeled compounds. in peripheral organs at baseline and after pretreatment with SAHA (1 mg/kg, 5 min before injection) showed no significant differences indicating that, similar to brain, there is no binding specificity in the major peripheral organs (Fig. 7) . Prior studies have shown that [ 18 F]FAHA has moderate brain penetration which is reduced by treatment with SAHA indicating that radioactivity accumulation in the brain is HDAC-specific. 14, 15 However, contrary to our prediction, the brain uptake of [ 11 C]3, which only differs from [ 18 F]FAHA by the substitution of a hydrogen atom for the fluorine atom in the acetyl group, was very poor (Fig. 4) . The difference is not due to different rates of metabolism; the fraction of [ Based on our results and prior studies, the most important physiological criterion to be optimized for the future development of HDAC radiotracers for brain studies is BBB permeability. In order to set the guideline of each molecular property known to affect BBB permeability, we compared lipophilicity (c log P) and polar surface area (PSA) for known HDAC inhibitors and radioligands as shown in Table 1 . Both molecular weight and c log P for all selected compounds were within acceptable ranges, where many conventional PET radiotracers also fall. 30 However, the PSA range is broad (73.6-107.1) and relatively high compared with conventional radiotracers. Lower PSA values are known to be associated with higher BBB permeability. For example, in a class-by-class comparison, the PSA of BBB permeable hydroxamate should be lower than that of the lowest PSA hydroxamate, [ 11 C]KB631 which showed little brain uptake. 20 In case of HDAC substrates, the PSA of com- 
